learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
Search
forLearn
5 / 801 resultslearn oligopeptide-71
learn Sodium PCA
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn sh-Polypeptide-7
Research
5 / 479 results
research Hydrogel microneedle delivery of a palmitoylated peptide promotes hair regeneration via dual activation of Wnt/β-catenin and cAMP–PKA signaling
A new peptide delivered through microneedles can effectively promote hair regrowth.
research PAK4 signaling in health and disease: defining the PAK4–CREB axis
PAK4 is crucial in cancer progression, brain development, and could be a therapeutic target, especially through the PAK4-CREB axis.
research Activation of cAMP Signaling in Response to α-Phellandrene Promotes Vascular Endothelial Growth Factor Levels and Proliferation in Human Dermal Papilla Cells
α-Phellandrene may help prevent hair loss by increasing growth factors and cell growth in hair cells through a specific signaling pathway.
research Cholesterol promotes hair growth through activating sympathetic nerves and enhancing the proliferation of hair follicle stem cells
Cholesterol helps hair grow by activating nerves and boosting hair follicle stem cells.
research Steroidogenic factor-1 lineage origin of skin lesions in Carney complex syndrome
Skin lesions in Carney complex are likely caused by a specific group of skin cells that promote pigment production due to a genetic mutation.
Community Join
5 / 1000+ resultscommunity The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
community Proposed new pathogenesis model for androgenetic alopecia (AGA)
The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.
community I have heard that Amplifica - Scube3 initiate a human study for AGA, but I cannot find any information about it from clinictrial.gov. Amplifica did not state it is a phase 1 clinic trial or not, it says it is "The initiation of our first-in-human clinical study"
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.